ellipse zum ausdrucken
Jennifer Zibuda, IR@portola.com. The boards of directors of both companies have unanimously approved the acquisition. AstraZeneca provides this link as a service to website visitors. Nothing contained in this area of the website should be construed as a profit estimate or profit forecast and no statement in this area of the website should be interpreted to mean that earnings per share of AstraZeneca or Alexion for the current or future financial years would necessarily match or exceed the historical published earnings per share of AstraZeneca or Alexion. Alexion has five approved products on the market today and a pipeline of product candidates in development. Alexion: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Chris Stevo, 857-338-9309 Head of Investor Relations Portola: Media Emily Faucette, Media@portola.com. Portola is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. All Alexion financial information in this announcement is presented following US GAAP and may be different in the Circular, which will be prepared under IFRS and AstraZeneca's accounting policies. (iv) The value placed by the acquisition on the entire issued and to be issued ordinary share capital of Alexion is to be calculated: • by reference to an equivalent value of $54.14 per AstraZeneca reference ADS; and. I have read this warning and will not be using any of the contained product information for clinical purposes. Evercore, Centerview Partners and Ondra, each of which is authorised and regulated by the Financial Conduct Authority in the United Kingdom, are each acting exclusively for AstraZeneca and no one else in connection with the transaction and the matters referred to in this document and will not regard any other person as a client in relation to the matters set out in this document and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to their respective clients, nor for providing advice in relation to the transaction or any other matter referred to in this document. This announcement has been prepared for the purpose of complying with the applicable law and regulation of the United Kingdom and the United States and information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws and regulations of jurisdictions outside the United Kingdom or the United States. This announcement is for informational purposes only and does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell Portola common stock. The presentation will be available at astrazeneca.com before the call takes place, and replay details after the call. Source: Alexion Pharmaceuticals, Inc. and Achillion Pharmaceuticals, Inc. Alexion: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, Investor Relations Achillion: Media Susanne Heinzinger, 215-709-3032 Senior VP, Corporate Communications Investors A. Clayton Robertson, 215-709-3078 Manager, Investor Relations In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of AstraZeneca. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency as well as the first and only approved Factor Xa inhibitor reversal agent. As a consequence of legal restrictions, the release, publication or distribution of information contained on this area of the website in certain jurisdictions or to certain persons may be restricted or unlawful. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Associate Director, Investor Relations at Alexion Pharmaceuticals, Inc. The Alexion proxy statement is also expected to be published in the first half of 2021. Investors Chris Stevo, 857-338-9309 Head of Investor Relations Portola: Media Emily Faucette, Media@portola.com Investors Jennifer Zibuda, IR@portola.com UK: +44 203 481 5237 In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good. As part of the acquisition, Alexion will also be acquiring cash currently on Portola’s balance sheet, net of debt of approximately $215 million that will become due upon closing. For general inquiries, please contact our Global Headquarters at 1-475-230-2596. By using our website, you agree to our use of cookies in accordance with our. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients. Scientific leadership - accelerated presence in immunology. The boards of directors of both Alexion and AstraZeneca have unanimously approved the proposed acquisition and resolved to recommend that their respective shareholders vote in favour of it. These forward looking statements include all matters that are not historical facts and involve predictions. Computershare Investor Services. We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics. Any failure to comply with this restriction may constitute a violation of such laws or regulations. Source: Alexion Pharmaceuticals, Inc. Alexion Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications. The acquisition is a Class 1 transaction for AstraZeneca and as such, will require the approval of its shareholders to comply with the UK Listing Rules. Password: 12121220. 06, 2020Corporate Participants: Chris Stevo — Head of Investor Relations. Alexion has exhibited skilful commercial execution in building its 'blockbuster' C5 franchise. Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2020 before the US financial markets open on February 4, 2021. Combining AstraZeneca’s capabilities in precision medicine and Alexion’s expertise in rare-disease development and commercialisation will enable the new company to develop a portfolio of medicines addressing the large unmet needs of patients suffering from rare diseases. Alexion, AstraZeneca and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Alexion shareholders in connection with the proposed transaction. Forward-looking statements may and often do differ materially from actual results. In particular, viewing this area of the website is not permitted if you are resident in Canada, Australia, Japan or South Africa. Head of Investor Relations, Portola: NASDAQ:ALXN opened at $154.86 on Wednesday. As of December 31, 2019, cash and short-term investments were approximately $430 million. Greater Boston Area 500+ connections. Over 7,000 rare diseases are known today, and only c.5% have US Food and Drug Administration-approved treatments.1 The global rare disease market is forecasted to grow by a low double digit percentage in the future.2. The bridge-financing facility is available for an initial term of 12 months from the earlier of the date of completion of the acquisition and 12 December 2021 with up to two six-month extensions available at the discretion of AstraZeneca. In connection with the proposed acquisition, AstraZeneca intends to file a registration statement on Form F-4 with the SEC, which will include a document that serves as a prospectus of AstraZeneca and a proxy statement of Alexion (the "proxy statement/prospectus"), Alexion intends to file a proxy statement with the SEC (the "proxy statement") and each party will file other documents regarding the proposed acquisition with the SEC. Good morning. RBC Capital Markets, LLC served as Alexion’s exclusive financial advisor. Associate Director, Investor Relations at Alexion Pharmaceuticals, Inc. 0001104659-21-035337.pdf. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP and should be reviewed in conjunction with the relevant GAAP financial measures. Chris Stevo, 857-338-9309 This … In addition, the Tender Offer Statement and other documents that Alexion and its acquisition subsidiary file with the SEC will be made available to all investors and security holders of Portola free of charge from the information agent for the tender offer. Cooley LLP served as Portola’s legal advisor. Non-GAAP results, determined in accordance with Alexion's internal policies, exclude the impact of the following GAAP items: share-based compensation expense, fair value adjustment of inventory acquired, amortisation of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on the sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. Join to Connect Alexion Pharmaceuticals, Inc. Bentley University. Associate Director, Investor Relations at Alexion Pharmaceuticals, Inc. Boston, Massachusetts 500+ connections. AstraZeneca, with Alexion's R&D team, will work to build on Alexion's pipeline of 11 molecules across more than 20 clinical-development programmes across the spectrum of indications, in rare diseases and beyond. Investor Relations Global Contacts Alexion Pharmaceuticals Inc ALXN Morningstar Rating Rating as of Mar 8, 2021. Ludwig Hantson-- Chief Executive Officer. The company was founded in 1992 and is headquartered in Massachusetts in the US. Alexion Pharmaceuticals is a biotechnology company focused on developing treatments for rare diseases. Information about the directors and executive officers of Alexion and their ownership of Alexion shares is set forth in the definitive proxy statement for Alexion’s 2020 special meeting of shareholders, as previously filed with the SEC on March 26, 2020. US: +1 301 715 8592, Webinar ID: 995 4603 8702 The actual amounts will be determined as of the transaction close. We remain committed to continuing to serve the patients who rely on our medicines and firmly believe the combined organisation will be well positioned to accelerate innovation and deliver enhanced value for our shareholders, patients and the rare disease communities.”. 425. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021, and upon completion, Alexion shareholders will own c.15% of the combined company. The International Securities Identification Number for the Alexion Shares is US0153511094. Company Secretary AstraZeneca remains committed to maintaining a strong investment-grade credit rating. January 5, 2021 As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). I represent and warrant to AstraZeneca that I intend to access this area of the website for information purposes only, that I have read and understood this notice and that I understand that it may affect my rights or responsibilities. This announcement is not a prospectus for the purposes of the UK Prospectus Regulation Rules or the EU Prospectus Regulation. Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion's Annual Report on Form 10-K for the year ended 31 December 2019, in each case as amended by any subsequent filings made with the SEC. A shareholder circular, together with notice of the relevant shareholder meeting, will be distributed to shareholders in the first half of 2021. To the fullest extent permitted by applicable law, each of Evercore, Centerview Partners and Ondra and each of their respective affiliates accordingly disclaim all and any responsibility or liability whether arising in tort, contract or otherwise (save as referred to above) which they might otherwise have in respect of this announcement or any statement contained therein. Source: Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. This transaction marks the start of an exciting new chapter for Alexion. Alexion and Portola disclaim any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. +1.64 (+1.1%) DATA AS OF Mar 05, 2021. I agree that I will not forward, transfer or distribute (by any means including by electronic transmission) any documents included in this area of the website either in whole or in part to any person in Canada, Australia, Japan or South Africa or any other jurisdiction where such distribution may be restricted by applicable law or regulation.
Ferrero Küsschen Glutenfrei, Dienstgrade Luftwaffe Offizier, Angelique Kerber Aktuell, Gemeinde Definition Für Kinder, Skat Lernen App, Antje Hagen Kinder, Geldkurs Briefkurs Import Export, An Die Freude Text,